Alnylam Pharmaceuticals has demonstrated significant progress in its recent financial results and strategic growth initiatives. The firm outperformed quarterly earnings estimates in 2024 while maintaining consistent growth. It also presented fiscal year 2024 financial results, with executives cashing in on company stocks. A pivotal moment was the completion of the first phase 1 clinical trial. The company's full year earnings, however, fell below expectations. Alnylam recently submitted a regulatory application for Vutrisiran for treating ATTR Amyloidosis with Cardiomyopathy to the EU. The CMO sold shares worth $14.99 million. They have also set ambitious targets, notably a $2.25B revenue target for 2025, driven by AMVUTTRA expansion. Their stock has been strong, with a surge after their heart disease drug succeeded. The company extended its partnership to commercialize RNAi therapeutics in LATAM and APAC. Notably, they achieved 96% TTR reduction in the Phase 1 ATTR Amyloidosis Trial, showing the promise of RNAi therapeutics.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Fri, 21 Feb 2025 16:58:23 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
